Australian scientists have discovered how the immune system can control melanoma, a mechanism which could be used to enhance cancer treatments.
Published today in Nature, Peter Doherty Institute for Infection and Immunity (Doherty Institute) and Telethon Kids Institute researchers investigated the role of a particular immune cell, tissue-resident memory T (TRM) cells, in controlling melanoma.
TRM cells were able to control the tumour in the mice for the life of the animal, which is likely to equate to decades of protection in humans.
University of Melbourne PhD student, Simone Park from the Doherty Institute, created an imaging model to study TRM cells’ and melanoma in a mouse model.
“Using a special microscope, we could see individual melanoma cells sitting in the skin of the mouse, and could watch the T cells move through the skin, find the melanoma cells and control the growth of those cells,” Ms Park explained.
One of the main issues for cancer patients is that there is always a risk that the tumour can come back years later, after surgery or chemotherapy.
Previous research has shown that small numbers of cancer cells persist in the body after treatment and that the immune system probably keeps the cancer cells under control but this study in mice could study the immune system directly. This is work that could never be done in people.
“I was able to see through moving images that these TRM cells are important for maintaining the control of the tumour cells; if you remove the TRM cells you have a break in that control and the cancer can start to grow back again,” Ms Park said.
“If you could make more of these TRM cells through immunotherapies, or enhance the activity of those that are already there in some way, you could boost anti-tumour immunity.”
Senior author on the paper, University of Melbourne Associate Professor Thomas Gebhardt, Laboratory Head at the Doherty Institute, said an increase of TRM cells has already been associated with better outcomes in cancer patients, but the way they work to suppress tumours has remained unknown.
“The principal of cutting-edge immunotherapies currently in clinical practise is that they generate a T-cell response. But if we can hone in on one type of T-cell – the TRM cells specifically, we could have an even bigger impact on stopping cancers from coming back,” Associate Professor Gebhardt said.
“We now have a much better understanding of which T-cells are important in controlling skin cancers and how those cells are working but there is still much more work to do to make these cells work even better,” Associate Professor Gebhardt said.
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
on January 22, 2019 at 5:30 pm
Evidence-based recommendations on nivolumab (Opdivo) for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease. Next review: More evidence ... […]
Melanoma Therapeutics Market Competitive Scenario, Drivers And Challenges Analysis Forecast 2026
on January 21, 2019 at 10:41 pm
Jan 22, 2019 (WiredRelease via COMTEX) -- Melanoma is a form of skin cancer that arises when pigment-producing cells mutates and become cancerous. Pigmented cells are found in skin and occur in other ... […]
Encorafenib/Binimetinib Combo Extends Survival in BRAF-Mutant Melanoma
on January 21, 2019 at 7:01 pm
The choice of medication or combination of medications for advanced melanoma has become increasingly challenging with the expanding armamentarium of effective treatments. Case in point, for melanoma p... […]
Dr. Ribas on Combination Immunotherapy and Radiation in Melanoma
on January 21, 2019 at 2:00 pm
Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses the potential for combination im... […]
NICE clears Pierre Fabre's targeted melanoma combo to take on Novartis, Roche drugs
on January 21, 2019 at 7:09 am
Thanks to new guidance from England’s drug cost watchdog, Novartis and Roche will be getting some new targeted melanoma competition from French pharma lab Pierre Fabre. In guidance published Friday, E... […]
Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma
on January 21, 2019 at 3:51 am
In European-descent populations, the majority of melanomas develop as a result of UV light exposure on hair-bearing skin, most commonly the trunk in men and the legs in women. Other subtypes of melano... […]
New nuclear medicine method could improve detection of primary and metastatic melanoma
on January 17, 2019 at 9:08 pm
A new nuclear medicine method for detecting malignant melanoma, one of the most aggressive skin cancers, has been successfully tested for the first time in humans and could improve detection of both p... […]
New PET probe could improve detection of primary and metastatic melanoma
on January 17, 2019 at 7:04 am
A new nuclear medicine method for detecting malignant melanoma, one of the most aggressive skin cancers, has been successfully tested for the first time in humans and could improve detection of ... […]
Hindering melanoma metastasis with an FDA-approved drug
on January 15, 2019 at 9:08 am
For cancer to spread, it needs a hospitable environment in distant organs. This fertile "soil" can provide a home to circulating malignant cells. Recent research has shown that cancer cells from ... […]
Innovations in Adjuvant Therapy for Melanoma
on January 14, 2019 at 9:47 am
If you’re living with melanoma, you may soon have access to a wider variety of therapies to prevent your cancer from coming back, especially in the field of adjuvant therapy. Adjuvant therapy for mela... […]
via Bing News